Oncology.TV

What's New in the Adjuvant Hormone Receptor-Positive Disease?

COMFORT II - Why is spleen volume so important? and other questions with Dr. Claire Harrison

ICON Meeting 2011: A Complex Family of Disease with Many Challenges - Dr.Grossman

AML On The Go - Management of the Older Adult WIth AML - Part 2 of 2

AML On The Go - Application of NGS In Newly Diagnosed AML

AML On The Go - AML: State of the Art and the Summer of 2017 Module 1 of 2

AML On The Go - PD-1/PD-L2 Expression is Upregulated by Epigenetic

Evaluation of BCR-ABL monitoring in Chronic Myelogenous Leukemia in clinical practice

AML On The Go - Impact of Patient Reported Symptoms on Physical

AML On The Go - Debate: Should MRD Monitoring in AML - Pro

AML On The Go - Debate: Should MRD Monitoring in AML...Con - Part 1 of 2

AMl On The Go - Should MRD Monitoring Debate Pro

120CML11

AMl On The Go - Gemtuzumab Ozogamicin in AML

AML On The Go - Emerging Immunotherapies in AML

AML On The Go - Immune Checkpoint based approaches in AML- Module 1 of 2

AML On The Go - Minimal Residual Disease Eradication with Epigenetic

120CML09

AML On The Go - The Next Questions - Module 1 of 2

120CML03

120CML13

120CML08

120CML12

120CML06